SYGNIS concludes agreement with Lucigen Corp. as a distributor for their NGS portfolio focused on the clinical oncology research market in the U.S.
- Lucigen, a U.S.-based Next Generation Sequencing (NGS) and life science research manufacturer, adds huge market potential for SYGNIS
- Partnership to open up the fast growing U.S. clinical oncology research market for SYGNIS’ NGS product lines
Madrid, Spain and Heidelberg, Germany, December 3rd, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a distribution agreement with Lucigen Corp. (Middleton, Wisconsin, USA) for the commercialization of SYGNIS’ proprietary product portfolio in the USA. In particular, Lucigen will focus on the clinical oncology research market where no-bias single cell amplification is of critical importance for NGS applications.
Under the terms of the agreement, SYGNIS has granted Lucigen non-exclusive rights to promote, market, and sell all existing and future SYGNIS product lines in the U.S. The partnership includes a focus on key opinion leaders in the U.S. with the goal to build a network of reference sites specializing in single cell amplification for NGS using SYGNIS’ revolutionary TruePrimeTM products for primer-free whole genome amplification (WGA). The agreement also includes SunScriptTM thermostable reverse transcriptase kits for the translation of RNA into DNA and the newly launched SunScriptTM One Step Reverse Transcriptase (RT)-PCR Kit for parallel transcription and amplification of genomic information.
Lucigen develops and distributes kits for the Next Generation Sequencing (NGS), life science and diagnostics industry worldwide and works with leading NGS companies to simplify and improve workflows.
“This agreement with Lucigen further opens the U.S. market for clinical oncology research applications where single cell amplification of tumor cell DNA is becoming widely used. Lucigen and the Mayflower agreement, announced earlier, will lead to a significant boost in awareness for our products worldwide,” said Pilar de la Huerta, CEO and CFO of SYGNIS. “Already, we have stated that 2016 will be the year we focus on the U.S. market and these agreements are paramount to this goal. More than 50% of the global NGS market is in the U.S. and we are now perfectly placed to open up this market. Lucigen and SYGNIS are very excited about the potential of this agreement.”
Visit our website for additional information on SYGNIS products: http://www.sygnis.com
TruePrimeTM is the brand name of a revolutionary novel MDA technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of SYGNIS proprietary DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand displacement capacity of the Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
SunScriptTM RT is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions for use e.g. in clinical diagnostics whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing (NGS) applications, in gene expression profiling and molecular diagnostics.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30